OncoMatch/Clinical Trials/NCT06668961
A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Is NCT06668961 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including SI-B001 and SI-B003 for head and neck squamous cell carcinoma.
Treatment: SI-B001 · SI-B003 — This study is a open, multi-center phase II clinical study to explore the efficacy, safety and pharmacokinetic/pharmacodynamic characteristics of SI-B001+SI-B003 combined with platinum-based chemotherapy as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
Exception: excluding treatment for locally advanced disease as part of multimodal therapy
received systemic therapy, excluding treatment for locally advanced disease as part of multimodal therapy
Cannot have received: immunotherapy
Exception: unless grade <3 irAE and grade <2 immune-related myocarditis
Had received immunotherapy and had grade ≥3 irAE or grade ≥2 immune-related myocarditis
Cannot have received: radiotherapy
Received radiotherapy within 4 weeks before the first dose of study drug
Cannot have received: traditional Chinese medicine with anti-tumor indications
Use of traditional Chinese medicine with anti-tumor indications within 2 weeks
Cannot have received: major surgery
Had undergone major surgery within 4 weeks before the first dose
Cannot have received: autologous or allogeneic stem cell transplantation
Had autologous or allogeneic stem cell transplantation
Lab requirements
Blood counts
No blood transfusion or colony-stimulating factor within 14 days before first use of study drug; organ function level must meet requirements
Cardiac function
No severe cardiac dysfunction, left ventricular ejection fraction ≥50%
No severe cardiac dysfunction, left ventricular ejection fraction ≥50%; No blood transfusion or colony-stimulating factor was allowed within 14 days before the first use of the study drug, and the organ function level must meet the requirements
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify